Aubrey Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Aubrey Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,847	Closed	-$227K	–	69
2023 Q4	$227K	Hold	1,847	–	–	0.1%	60
2023 Q3	$226K	Hold	1,847	–	–	0.13%	53
2023 Q2	$229K	Hold	1,847	–	–	0.15%	48
2023 Q1	$270K	Hold	1,847	–	–	0.16%	43
2022 Q4	$294K	Hold	1,847	–	–	0.24%	39
2022 Q3	$246K	Hold	1,847	–	–	0.21%	39
2022 Q2	$288K	Hold	1,847	–	–	0.23%	43
2022 Q1	$288K	Sell	1,847 -700	-27%	-$102K	0.16%	56
2021 Q4	$324K	Buy	2,547 +250	+11%	+$32.9K	0.13%	35
2021 Q3	$299K	Sell	2,297 -508	-18%	-$76.8K	0.09%	36
2021 Q2	$498K	Hold	2,805	–	–	0.15%	31
2021 Q1	$461K	Buy	+2,805	New	+$462K	0.13%	35

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Aubrey Capital Management's JAZZ Position: Q1 2024 in Review

Aubrey Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 1,847 shares — an estimated $227K sold.

Aubrey Capital Management first reported a position in JAZZ in Q1 2021 and held it in 12 quarters. The position peaked at $498K in Q2 2021. 481 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

Aubrey Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Aubrey Capital Management sold 1,847 Jazz Pharmaceuticals shares in Q1 2024, an estimated $227K.
Aubrey Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2021 and held it in 12 quarters.
Aubrey Capital Management's Jazz Pharmaceuticals position peaked at $498K in Q2 2021.
481 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Aubrey Capital Management's 13F filing for Q1 2024, filed 25 Apr 2024.